Argenx to Acquire Forte Biosciences for About $2.2 Billion

• The deal is valued at about $2.2 billion with argenx paying $77 per share
• The primary asset being acquired is FB102, an experimental drug for autoimmune conditions currently in development
• The acquisition expands argenx's immunology pipeline and strengthens its position in the autoimmune disease treatment market

Summary: Argenx Acquires Forte Biosciences for $2.2 Billion

Key Transaction Details:

Belgian-Dutch immunology company argenx has announced the acquisition of Forte Biosciences for approximately $2.2 billion. The deal values Forte shares at $77 each.

Strategic Rationale:

The acquisition enables argenx to add FB102, an experimental autoimmune drug, to its product portfolio. This move expands argenx's pipeline in the immunology and autoimmune disease treatment space.

Companies Involved:

• Argenx: Acquirer, Belgian-Dutch immunology-focused pharmaceutical company
• Forte Biosciences: Target company, developer of experimental autoimmune therapies

Market Implications:

This transaction represents a significant consolidation move in the immunology sector, demonstrating argenx's commitment to expanding its autoimmune disease franchise through strategic M&A. The $2.2 billion valuation suggests strong confidence in FB102's commercial potential and clinical prospects. The deal provides Forte shareholders with a substantial premium, while argenx gains access to a potentially differentiated asset in the competitive autoimmune therapeutics market.

The acquisition reflects broader industry trends of larger biotechnology companies acquiring clinical-stage assets to bolster their pipelines and diversify revenue streams. For investors, this signals argenx's aggressive growth strategy and willingness to deploy significant capital for pipeline expansion.

Announcement Date: July 27 (Reuters)

The transaction is subject to standard regulatory approvals and closing conditions, though specific timeline details were not disclosed in the announcement.